Press Enter to search · Esc to close
A new peer-reviewed review argues the panic over muscle loss with weight-loss drugs may be missing the point. The real question is whether your muscle still works — not what the scale partitions.
A new NHANES analysis suggests a simple index pulled from a routine CBC — the Systemic Immune-Inflammatory Index — tracks with mortality risk in metabolic syndrome. Here's what it is, and what it isn't.
A new phase 3 trial shows a once-daily pill can deliver meaningful weight loss without a needle — and that small detail could change who actually gets treated.
New research links a combined insulin-resistance and frailty score to liver disease, ties everyday nutrients to kidney-heart-metabolic mortality, and uses a mouse model to ask why some bodies lose muscle while others don't.
Two new population studies suggest the cholesterol number on your lab slip may be quietly underselling your real cardiovascular risk — especially if you're carrying belly weight or creeping insulin resistance.
A new composite index built from C-reactive protein, triglycerides and glucose tracked 7,280 adults for nearly a decade — and outperformed its parts at flagging who progressed.
Early science suggests the metabolic chaos behind type 2 diabetes may also drive memory loss and silent artery damage — and that treating one upstream signal could ripple downstream.
A new systematic review argues the number on your cholesterol panel misses the molecular story — and a parallel mortality analysis suggests insulin resistance and kidney function deserve a seat at the table.
A new review reframes Alzheimer's risk around peripheral insulin resistance — not blood sugar itself — and points to tiny cellular couriers as possible carriers of metabolic damage to the brain.
Metabolic dysfunction-associated fatty liver disease has slipped into the mainstream of metabolic health. Here's what the newest evidence says about screening, food, and the people most at risk.